The board of directors of Genor Biopharma Holdings Limited announced that, on 13 March 2024, the China National Medical Products Administration (NMPA) for GB491 (Lerociclib) combined with Letrozole for the treatment of HR-positive, HER2-negative patients with advanced breast cancer who have not previously undergone systemic antitumor therapy. Previously, the NDA for GB491 (LerOCiclib) in combination with Fulvestrant as the treatment of HR+/HER2- locally advanced or metastatic breast cancer patients with disease progression following previous endocrine therapy was accepted by the NMPA on 28 March 2023, and has successfully completed clinical on-site inspection.